Despite disappointments in the hunt for effective fat-busting drugs, this large and seemingly ever-growing market is encouraging companies to continue to rise to the challenge of a disease that is a host of interacting disorders.
by Melanie A. Senior
Obesity affects more than a fifth of the adult population in the US and Germany, and more than 15% in the UK (see Exhibit 1). Yet it's only in the...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.
US green light will further expand sales of the prostate cancer blockbuster.
Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.
Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.
Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.
All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.
The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.
